SR One Capital Management

SR One Capital Management is a transatlantic biotechnology venture capital firm specializing in early-stage and growth investments in life sciences companies globally. The firm focuses on therapeutics, medical devices, and healthcare services, aiming to translate innovative technologies into next-generation medicines for patients with significant unmet medical needs. SR One operates offices in Redwood City, California; Wayne, Pennsylvania; and London, United Kingdom, providing a strategic presence in key biotechnology hubs.

The firm's investment strategy emphasizes a 'back-and-build' approach, partnering with entrepreneurs and scientists to develop companies with strong underlying science and clear development pathways. SR One seeks to foster the growth of its portfolio companies by offering both financial support and strategic guidance, aiming to accelerate the development and commercialization of innovative medical technologies.

Since its spin-out from GlaxoSmithKline in 2020, SR One has raised over $1 billion and founded or invested in over 20 companies. The firm's leadership has extensive experience in building and investing in biotechnology companies, working together for more than a decade to support the growth and success of its portfolio companies.